Unexplained weight loss (UWL) is a common yet perplexing clinical presentation, often posing significant diagnostic challenges for clinicians. While it may be an indicator of underlying malignancy, infection, or other systemic diseases, in many instances, no clear etiology is found despite comprehensive evaluation.
The first step involves a comprehensive history and physical examination. Attention should be given to dietary intake, gastrointestinal symptoms, and psychosocial factors. Additionally, a review of medications can reveal possible iatrogenic causes. The physical examination should focus on signs of malnutrition, cachexia, and evidence of systemic disease.
Initial laboratory studies should include a complete blood count, comprehensive metabolic panel, thyroid function tests, and inflammatory markers. If these are inconclusive, further testing such as imaging studies or endoscopies may be warranted. However, the yield of these tests is often low without specific indications.
In elderly patients, UWL may be a sign of frailty or sarcopenia. In such cases, a comprehensive geriatric assessment can be beneficial. For patients with psychiatric symptoms, a thorough mental health evaluation is necessary as depression and anxiety are common causes of UWL.
Management is primarily directed at the underlying cause, if identified. In cases where no cause is found, emphasis should be placed on nutritional support and regular follow-up to monitor for the development of new symptoms or signs. It's crucial to maintain a high index of suspicion for serious underlying disease, especially in patients with significant weight loss.
Evaluating UWL requires a methodical and patient-centered approach. While it can be a diagnostic quandary, a comprehensive approach can help identify the cause in most patients, guiding appropriate treatment and follow-up. Continued research is needed to improve our understanding and management of this complex clinical scenario.
1.
Injecting PD-1 Drug Directly Into Oral Precancers Shrinks Lesions
2.
Sevabertinib Approved for First-Line Mutated NSCLC
3.
After three years, responses to mounetuzumab in follicular lymphoma are still stable.
4.
FDA Bans Red Dye No. 3 From Foods, Ingested Drugs
5.
AI can identify women at risk of breast cancer years in advance: Study
1.
Revolutionizing Cancer Treatment: Advances in Immunotherapy and Cell Therapy
2.
Pediatric Tumor Microenvironment Evolution: Mechanisms, Clinical Impact, and Therapeutic Implications
3.
Hematopoietic Stem Cell Activity Biomarkers in Aging
4.
Bone-Marrow Immune Cell Competition: Mechanisms, Clinical Implications, and Emerging Therapeutic Perspectives
5.
The Truth About TAR Syndrome: Understanding the Rare Genetic Disorder
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII
2.
A New Era in Managing Cancer-Associated Thrombosis
3.
Emerging Concepts in Hematology
4.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management- Further Discussion
5.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation